Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hubei Yizhi Konjac Biotechnology is a leading specialized enterprise focused on the research, development, and deep processing of konjac (Amorphophallus konjac) for health and industrial applications. The company utilizes advanced extraction and physical modification technologies to produce high-purity konjac glucomannan, which serves as a functional ingredient in dietary supplements, pharmaceutical excipients, and healthy food products. Their portfolio extends beyond nutrition into biotechnology applications, including the development of konjac-based hydrogels and biodegradable materials for cosmetics and medical use. Listed on the Beijing Stock Exchange, the company is recognized as a key innovator in the global polysaccharide market, providing natural, low-calorie solutions for metabolic health and weight management.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hubei Yizhi Konjac Biotechnology.